Spyre Therapeutics, Inc. (SYRE) stock
SYRENasdaqPharmaceutical PreparationsFiscal year ends December 31
$101.46+7.65 (+8.15%)
Close on Nov 18, 2026Market cap $8.95BP/E –Yield –
Spyre Therapeutics profit margin
Profit margin (net margin) is net income as a percentage of revenue.
Spyre Therapeutics's profit margin for the twelve months ending Mar 31, 2024 was -52939.7%. For fiscal 2023 it was -38238.1%, against -3598.8% the year before. The highest annual figure on record is -351.1% in fiscal 2021.
Annual profit margin
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| FY2023 | Dec 31, 2023 | -38238.1% | −34639.4 |
| FY2022 | Dec 31, 2022 | -3598.8% | −3247.6 |
| FY2021 | Dec 31, 2021 | -351.1% | +789.5 |
| FY2018 | Dec 31, 2018 | -1140.6% | −617.4 |
| FY2017 | Dec 31, 2017 | -523.3% | −54.4 |
| FY2016 | Dec 31, 2016 | -468.8% | – |
Quarterly profit margin
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| Q2 FY2023 | Jun 30, 2023 | -31552.5% | −27980.8 |
| Q1 FY2023 | Mar 31, 2023 | -9304.0% | −7509.9 |
| Q4 FY2022 | Dec 31, 2022 | -11203.6% | −10642.5 |
| Q3 FY2022 | Sep 30, 2022 | -10479.3% | −9027.8 |
| Q2 FY2022 | Jun 30, 2022 | -3571.7% | −3521.8 |
| Q1 FY2022 | Mar 31, 2022 | -1794.1% | −1398.2 |
| Q4 FY2021 | Dec 31, 2021 | -561.1% | −23.4 |
| Q3 FY2021 | Sep 30, 2021 | -1451.5% | −1014.4 |
| Q2 FY2021 | Jun 30, 2021 | -49.9% | +574.6 |
| Q2 FY2018 | Jun 30, 2018 | -395.9% | +52.5 |
| Q1 FY2018 | Mar 31, 2018 | -537.7% | +98.5 |
| Q4 FY2017 | Dec 31, 2017 | -437.2% | – |
| Q3 FY2017 | Sep 30, 2017 | -624.4% | – |
| Q2 FY2017 | Jun 30, 2017 | -448.4% | – |
| Q1 FY2017 | Mar 31, 2017 | -636.2% | – |
See a number that looks wrong?